Making Sense of a Positive Genetic Test Result for Huntington Disease
Meaning Making Among Asymptomatic Individuals With a Positive Presymptomatic Genetic Test Result for Huntington Disease
This exploratory study will examine ways in which individuals approach a positive genetic test for Huntington Disease (HD). HD is a neurodegenerative disorder that causes emotional, cognitive, and movement problems, and currently there is no way to prevent, stop or reverse the progression of the disease. It is passed down through a mutation in a normal gene, and each child of an HD parent has a 50-50 chance of inheriting the HD gene. The study is designed to explore how individuals adjust to their new genetic status and evaluate any perceived mental or emotional barriers to that adjustment. Currently, little is known about how individuals come to terms with a positive genetic test result for a condition that has no known cure or effective treatment. The results of this study may give health care providers and counselors more information about how to help patients who are at risk for developing HD make sense of their new genetic status.
Candidates will be prescreened and referred to the study by clinics that specialize in genetic testing and counseling. Candidates must be 18 years old or older and must have received a positive genetic test result for HD at least one month prior to the study. They must also perceive themselves to be asymptomatic-that is, without existing HD symptoms.
During the study, participants will be interviewed and asked a series of questions about their decision to pursue testing, their life since the testing, and the things that they have found helpful or unhelpful since receiving the test results. The interviews will be recorded and will last approximately 60 minutes. Participants also will receive a follow-up phone call within two to three days to ensure their general psychological well-being after the interview.
Visão geral do estudo
Status
Condições
Descrição detalhada
Huntington Disease (HD) is a progressive neurological condition, eventually leading to death. Presymptomatic, predictive genetic testing can inform individuals of their genetic status. A positive genetic test result can be a threatening event. In adapting to threatening events people often try and find meaning in the experience. Meaning making refers to the attempt to understand an event or experience and its significance in the context of one's life. The search for meaning can eventually lead to acceptance of an event or experience, and is considered an important component of adaptation. Although it has been established that testing for HD can be a significantly stressful event, and that meaning making is a frequent response towards adaptation, little is known about this process among individuals faced with a positive genetic test result for HD. This study will describe meaning making in a population of presymptomatic individuals with a positive genetic test result for HD.
Semi-structured interviews will be conducted, recorded, transcribed, and analyzed. A typology of common themes will be compiled and reported. Data gathered from these interviews will improve understanding of the phenomenon of meaning making in this population, and will contribute to the existing literature on the role of meaning making in cognitive adaptation. This study will specifically help gain insight into the process of meaning making among individuals who have tested positive for HD, and may potentially inform the ways in which health care professionals can help facilitate meaning-making among this population, in their process of adaptation to a stressful live event.
Tipo de estudo
Inscrição
Contactos e Locais
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Johns Hopkins University
-
Bethesda, Maryland, Estados Unidos, 20892
- National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15261
- University of Pittsburgh
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
- ELIGIBILITY CRITERIA:
Participants for this study will be men and women, age 18 or older, who have undergone presymptomatic genetic testing for HD, received a positive test result and currently perceive themselves as being asymptomatic. To obtain a range of experiences, the investigator (PR) will attempt to recruit individuals with a range of elapsed time since their positive test result.
INCLUSION CRITERIA:
- 18 years or older
- Able to speak and understand English
- Received results that they believe are positive at least one month ago
- Perceive themselves to be asymptomatic
- Willing and able to read and describe the consent form before the phone interview
EXCLUSION CRITERIA:
- Test result less than a month ago
- Believe that they got a negative test result
- Believe themselves to be symptomatic
- Obvious symptoms of dementia or serious mental illness that would preclude consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Daaleman TP, Frey BB, Wallace D, Studenski SA. Spirituality Index of Well-Being Scale: development and testing of a new measure. J Fam Pract. 2002 Nov;51(11):952.
- Decruyenaere M, Evers-Kiebooms G, Cloostermans T, Boogaerts A, Demyttenaere K, Dom R, Fryns JP. Psychological distress in the 5-year period after predictive testing for Huntington's disease. Eur J Hum Genet. 2003 Jan;11(1):30-8. doi: 10.1038/sj.ejhg.5200913.
- Bowes DE, Tamlyn D, Butler LJ. Women living with ovarian cancer: dealing with an early death. Health Care Women Int. 2002 Feb;23(2):135-48. doi: 10.1080/073993302753429013.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Distúrbios Neurocognitivos
- Doenças Genéticas, Congênitas
- Doenças dos Gânglios da Base
- Distúrbios do Movimento
- Doenças Neurodegenerativas
- Discinesias
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Demência
- Distúrbios Cognitivos
- Coréia
- Doença de Huntington
Outros números de identificação do estudo
- 999908005
- 08-HG-N005
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Huntington
-
University of HullRetirado
-
Sanguine BiosciencesHoffmann-La RocheRecrutamentoDoença de Huntington | Demência de Huntington | Doença de Huntington, Início Tardio | Huntington; Demência (Etiologia)Estados Unidos
-
Rush University Medical CenterRecrutamentoDoença de Huntington (HD)Estados Unidos
-
Skyhawk Therapeutics, Inc.Inscrevendo-se por conviteDoença de Huntington (HD)Austrália
-
University of IowaThe University of Texas Health Science Center, Houston; Children's Hospital... e outros colaboradoresAtivo, não recrutandoDoença de Huntington Juvenil | Doença de Huntington de Início JuvenilEstados Unidos
-
Fundació Institut de Recerca de l'Hospital de la...Ativo, não recrutando
-
PrileniaConcluídoVoluntários de Saúde, Doença de HuntingtonAlemanha
-
SOM Innovation Biotech SAConcluído
-
Massachusetts General HospitalConcluídoDoença de Huntington (HD)Estados Unidos
-
Neurocrine BiosciencesHuntington Study GroupConcluídoCoréia, HuntingtonEstados Unidos, Canadá